Skye Bioscience (SKYE) Stock Climbs Sharply Following Promising Drug Presentation
As of Tuesday’s market close, shares of Skye Bioscience, Inc. (NASDAQ: SKYE) had jumped 18.81% to $3.41, driven by a slew of positive developments on its main anti-obesity candidate, nimacimab. The company’s involvement in important scientific and investor gatherings, such as the American Diabetes Association’s (ADA) 85th Scientific Sessions, which took place in Chicago from […]